Arcturus Therapeutics: Buy Rating Affirmed Amid Promising OTC Developments and Upcoming CF Catalyst

Analyst Yigal Nochomovitz from Citi maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) and keeping the price target at $47.00.

Yigal Nochomovitz has given his Buy rating due to a combination of factors that suggest potential growth for Arcturus Therapeutics. The recent developments in their Over-the-Counter (OTC) readout have been favorable, and there is an anticipated catalyst in the cystic fibrosis (CF) program expected in early Q3 2025, which could drive the stock’s valuation upward.
Despite the stock trading slightly above cash, Nochomovitz sees a high-conviction opportunity for upside within the next 90 days. While the CF program presents some variability due to the FEV1 endpoint, which depends on patient lung function and effort, the overall outlook remains positive, justifying the Buy rating.